

Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Shubhasree Banerjee¹ · Ann Biehl² · Massimo Gadina³ · Sarfaraz Hasni⁴ · Daniella M. Schwartz⁵

Published online: 1 April 2017
© Springer International Publishing Switzerland 2017

Erratum to: *Drugs* 77:521–546 (2017) DOI 10.1007/s40265-017-0701-9

Page 537, Section 5.3.2 Filgotinib GLPG0634, last paragraph

The last sentence which currently reads:

Notably, a trial in patients with SLE was closed for lack of efficacy [171]

Should be deleted as this trial does not relate to Filgotinib

The online version of the original article can be found under doi:[10.1007/s40265-017-0701-9](https://doi.org/10.1007/s40265-017-0701-9).

✉ Shubhasree Banerjee
shubhasree.banerjee@nih.gov

- ¹ Rheumatology Fellowship and Training Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA
- ² Clinical Center, National Institutes of Health, Bethesda, USA
- ³ Translational Immunology Section, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA
- ⁴ Lupus Clinical Research Program, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA
- ⁵ Molecular Immunology and Inflammation Branch, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA